o2h group seeds new ideas in science, technology and green innovation. We work across boundaries and take a collaborative and shared approach to innovation, and therefore we co-invest, co-create and co-execute to bring these ideas to life. o2h is organised into 6 symbiotic verticals; o2h ventures, o2h discovery, o2h therapeutics, o2h technology, o2h co-work, and o2h community. o2h ventures is an engine for nurturing early stage life science and technology assets through seed investment. o2h Discovery is an integrated chemistry and biology services platform for executing collaborative research. o2h technology works on proprietary software projects for in-house portfolio companies. o2h Therapeutics is a seeding a novel pipeline of proprietary pre-clinical IP in Immunoncology (glioblastoma, breast cancer), anti-ageing and diabetes. o2h co-working space located in Hauxton, Cambridge, UK and o2h community covers our work with local non-profits organisations, our interests in working with social enterprise and our work in creating a community of innovators that can impact society. o2h group is co-located in Ahmedabad, India and in Cambridge UK. Please see www.o2h.com for more details.
Location: India, Gujarat, Ahmedabad
Phone: +91 2717 656 408
Founded date: 2005
Investors 1
| Date | Name | Website |
| - | Delin Vent... | delinventu... |
Mentions in press and media 25
| Date | Title | Description |
| 14.01.2026 | OutSee Secures £2.5M, Propels AI Genomics for Drug Discovery | OutSee secured a significant £2.5M seed funding round. Ahren Innovation Capital spearheaded the investment. This capital fuels OutSee's groundbreaking AI-powered Nomaly platform. Nomaly uses a "genomics-first" approach. It predict... |
| 12.01.2026 | OutSee: £2.5 Million Seed Round Completed And Partnership With o2h Discovery | OutSee, an AI-enabled genomics and drug discovery company, has closed a £2.5 million seed funding round and signed a strategic agreement with o2h discovery to begin a collaborative drug discovery programme around OutSee’s lead drug target c... |
| 11.09.2024 | PhoreMost raises £33M to advance 'Drugging the Undruggable' research | PhoreMost, the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, has completed an oversubscribed £33 million Series B investment round. PhoreMost’s SITESEEKER platform can identify the best new the... |
| 08.08.2024 | Healx Secures $47 Million to Tackle Rare Diseases with AI Innovations | In a significant leap for the biotech sector, Healx, a clinical-stage company based in Cambridge, UK, has successfully raised $47 million in a Series C funding round. This infusion of capital is not just a financial boost; it’s a lifeline f... |
| 07.08.2024 | Healx: Clinical-Stage Biotech Company Secures $47 Million In Series C | Healx, an AI-enabled, clinical-stage biotech company specializing in rare diseases, announced it has raised $47 million in a Series C round. This Series C round was co-led by Silicon Valley-based R42 Group and Atomico, one of Europe’s large... |
| 19.06.2024 | As Cambridge Wide Open Day buzzes in 2024, get set for Cambridge Wide Open Week in 2025! | The 2nd annual Cambridge Wide Open Day (CWOD) event had Cambridge buzzing last week with curious residents as well as people attending from as far afield as Birmingham and Nottingham, and even Switzerland and the US! Initial figures suggest... |
| 10.01.2023 | o2h technology launches the tech kickstarter competition to support seed stage companies with their tech development needs | Cambridge, UK - o2h technology, a business vertical of the o2h group, is excited to announce the launch of the o2h tech kickstarter competition exclusively for seed stage life science, greentech, and tech/AI companies to help them boost the... |
| 14.06.2022 | Spirea, a startup developing antibody drug conjugates in cancer, nabs $3 million | Cambridge-based biotech company Spirea has raised $3 million to advance a new generation of antibody drug conjugate (ADC) therapeutics. The round was co-led by Jonathan Milner and Cambridge Enterprise, with backing from R42 Group, ACF Inves... |
| 24.09.2021 | o2h co-work labs launches the world’s first influencer biotech bootcamp | o2h co-work labs launches the world’s first influencer biotech bootcamp 24-09-2021 o2h co-work labs, a business unit of o2h Group, is delighted to launch the first ever influencer biotech bootcamp covering representatives from the quintet i... |
| 24.09.2021 | o2h co-work labs launches the world’s first influencer biotech bootcamp | o2h co-work labs, a business unit of o2h Group, is delighted to launch the first ever influencer biotech bootcamp covering representatives from the quintet influencer community that are the creative forces driving biotech. The event will be... |
Show more